Canada Pension Plan Investment Board Ultragenyx Pharmaceutical Inc. Transaction History

Canada Pension Plan Investment Board

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$37.42 - $51.61 $374 - $516	-10 Reduced 0.33%	3,000 $123,000
Q1 2022 May 13, 2022	SELL	$62.2 - $84.4 $169,992 - $230,665	-2,733 Reduced 47.59%	3,010 $219,000
Q4 2021 Feb 14, 2022	SELL	$73.71 - $87.86 $395,011 - $470,841	-5,359 Reduced 48.27%	5,743 $483,000
Q3 2021 Nov 15, 2021	BUY	$77.92 - $102.4 $715,305 - $940,032	9,180 Added 477.63%	11,102 $1 Million
Q2 2021 Aug 16, 2021	BUY	$92.19 - $115.71 $37,982 - $47,672	412 Added 27.28%	1,922 $183,000
Q1 2021 May 17, 2021	BUY	$106.9 - $167.73 $160,350 - $251,594	1,500 Added 15000.0%	1,510 $172,000
Q4 2020 Feb 17, 2021	SELL	$84.4 - $177.39 $514,840 - $1.08 Million	-6,100 Reduced 99.84%	10 $1,000
Q3 2020 Nov 12, 2020	SELL	$72.98 - $90.0 $1.02 Million - $1.26 Million	-13,990 Reduced 69.6%	6,110 $502,000
Q2 2020 Aug 14, 2020	SELL	$46.91 - $78.22 $23,455 - $39,110	-500 Reduced 2.43%	20,100 $1.57 Million
Q4 2019 Feb 14, 2020	BUY	$36.08 - $45.83 $303,216 - $385,155	8,404 Added 68.91%	20,600 $880,000
Q3 2019 Nov 12, 2019	SELL	$42.5 - $63.11 $263,670 - $391,534	-6,204 Reduced 33.72%	12,196 $522,000
Q2 2019 Aug 12, 2019	BUY	$54.93 - $74.36 $1.01 Million - $1.37 Million	18,400 New	18,400 $1.17 Million
Q1 2018 May 14, 2018	SELL	$44.33 - $58.52 $279,279 - $368,676	-6,300 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$43.54 - $57.32 $4,354 - $5,732	100 Added 1.61%	6,300 $292,000
Q3 2017 Oct 30, 2017	BUY	$49.79 - $66.32 $308,698 - $411,183	6,200	6,200 $330,000

326

85.7M

520K

406K

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $3.01B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

Get notified when there are updates to the investment portfolio of Canada Pension Plan Investment Board, based on Form 13F filings with the SEC.

Stay updated on Canada Pension Plan Investment Board with notifications on news.